Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01410123 · ClinicalTrials.gov registry record · NA

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

A NA study of HIV and Hepatitis C, sponsored by Yale University.

Completed
Registry status
NA
Development phase
319
Enrollment target
5
Study locations

NCT01410123: Completed NA study of HIV and Hepatitis C, sponsored by Yale University.

NCT01410123 is a NA study of HIV and Hepatitis C that has completed, run by Yale University. The registered enrollment target is 319 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (27% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01410123, a NA study of HIV and Hepatitis C, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
319 participants
Enrollment target
5
Study locations

Study Summary

The study is a series of 3 linked randomized clinical trials of 6 month duration, with a total of 12 month follow-up, to evaluate the effect of Integrated Stepped Care on drinking outcomes and HIV biologic markers (including VACS index) in HIV-infected patients with unhealthy alcohol use.

Interventions

  • OTHER Treatment as Usual
  • OTHER Integrated Stepped Care (ISC)

Study Locations (5)

Texas

  • Dallas VA Medical Center - Dallas
  • VAMC Houston - Houston

District of Columbia

  • Washington DC VAMC - Washington D.C.

Georgia

  • VAMC Atlanta - Atlanta

New York

  • New York VAMC - New York Harbor Healthcare System - New York

Trial Details

FieldValue
Enrollment Target 319 participants
Start Date 2013-01
Est. Completion 2018-08-31
Phase NA
Yale University

1,492 total trials

What the finished NCT01410123 record still lists

NCT01410123 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (27% lower).

The record links to 4 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual is the first listed.

NCT01410123 lists 5 locations in 4 states (Texas, District of Columbia, Georgia).

Frequently Asked Questions

What is clinical trial NCT01410123 about?

NCT01410123 is a clinical study titled "Integrated Stepped Care for Unhealthy Alcohol Use in HIV". The study is a series of 3 linked randomized clinical trials of 6 month duration, with a total of 12 month follow-up, to evaluate the effect of Integrated Stepped Care on drinking outcomes and HIV biologic markers (including VACS index) in HIV-infected patients with unhealthy alcohol use.

What is the current status of trial NCT01410123?

This trial is currently completed. It is a NA study. The enrollment target is 319 participants. The study started on 2013-01. Estimated completion is 2018-08-31.

What conditions does trial NCT01410123 study?

This clinical trial studies the following conditions: HIV, Hepatitis C, Alcoholism, Liver Diseases, Alcoholic.

What interventions are being tested in trial NCT01410123?

The interventions under investigation include: Treatment as Usual (OTHER), Integrated Stepped Care (ISC) (OTHER).

Who is sponsoring clinical trial NCT01410123?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01410123 being conducted?

This trial has 5 study locations across District of Columbia, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01410123's enrollment target sits among peer trials

319 66th of 303 higher than 238 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05377996 · 319 participants · Phase 1

    A Study of XMT-1660 in Participants With Solid Tumors

  • NCT02763683 · 320 participants

    Investigations of Dementia in Parkinson Disease

  • NCT03331198 · 320 participants · Phase 1

    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  • NCT03458832 · 320 participants

    Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01410123, the US trial registry maintained by the National Library of Medicine. NCT01410123 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.